ReviewDiscover nano2026
Fluorescence-based biosensing with DNA nanostructures and DNA origami: from programmable architectures to quantitative readouts.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
DNA nanotechnology and DNA origami have emerged as promising platforms for biosensing by exploiting the programmability of DNA sequences and structural self-assembly. Diverse DNA nanostructures, including three-way junctions (TWJs), dendritic assemblies, hydrogels, and tetrahedral DNA nanostructures (TDNs), provide structurally defined frameworks for the organization of functional components. DNA origami further enables highly programmable and precise spatial positioning by folding long DNA scaffolds with multiple staple strands. Their high biocompatibility and nanoscale spatial addressability allow the controlled organization of fluorophores, quenchers, aptamers, nanoparticles, and other functional components, which is particularly advantageous for fluorescence-based sensing strategies that rely on precise spatial control of these components. In this review, we first introduce the fundamental principles of fluorescence-based biosensing, including Förster resonance energy transfer (FRET) and plasmon-enhanced fluorescence (PEF). Then categorize DNA nanostructure-based fluorescence biosensors according to their structural architectures and sensing mechanisms. DNA origami-based platforms are subsequently classified based on their signal transduction strategies. Representative studies are discussed in terms of their design principles and sensing performance. We further critically discuss the remaining challenges, including structural stability, scalability, signal reproducibility, and clinical translation, and provide perspectives on the future development of next-generation fluorescence biosensing platforms enabled by programmable DNA architectures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.